Latest news

• Pfizer gets first FDA nod for hedgehog inhibitor in AML

  And in a bumper day for the therapeutic category, the FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethyelating agent (azacitidine or decitabine) for the exact

• Celgene, Agios get FDA OK for leukaemia drug Idhifa

  At Celgene, enasidenib will slot into its blood cancer therapy portfolio alongside Vidaza (azacitidine), a drug used first-line to treat AML patients who cannot receive a stem cell transplant, which

• Celgene joins PD-1 race via partnership with BeiGene

  BeiGene is also acquiring Celgene's commercial operations in Asia with the right to sell blood cancer therapies Revlimid (lenalidomide) and Vidaza (azacitidine) and Abraxane (albumin-bound paclitaxel) for pancreatic cancer -

• Celgene bags US priority review for cancer metabolism drug

  For Celgene, enasidenib will slot into its haematological malignancy portfolio alongside Vidaza (azacitidine), a drug used first-line to treat AML patients who cannot receive a stem cell transplant and which

• AZ, BMS and Boehringer among UK Prix Galien finalists

  Pompe Disease. azacitidine. Vidaza. Celgene. Myslodysplastic Syndrome. omalizumab. Xolair. Novartis. Sever persistent allergic asthma.